FLOWTEC BIOTECH LTD

Executive Summary

Flowtec Biotech Ltd is a newly incorporated micro entity with positive net current assets and no regulatory compliance issues, indicating low immediate financial risk. However, its limited operating history, small scale, and modest net asset base warrant further due diligence focused on business viability and cash flow stability. Overall, the company presents a cautious but low-risk profile for investors at this stage.

FLOWTEC BIOTECH LTD - Analysis Report

Company Number: 14567629

Analysis Date: 2025-07-20 15:50 UTC

1. Risk Rating: LOW

Based on the available financial and company data, Flowtec Biotech Ltd exhibits a low risk profile at this early stage. The company is active, compliant with statutory filings, and has positive net current assets with a modest but positive net asset position.

2. Key Concerns:

• Limited Operating History: Incorporated in January 2023, the company has a very short track record, which limits the ability to assess operational stability and financial trends.
• Small Scale and Micro Entity Status: As a micro entity with only four employees, the business may face challenges scaling or absorbing shocks without a broader financial base.
• Modest Net Asset Base: Net assets stand at £16,830, which is low and could constrain the company’s ability to meet unexpected liabilities or invest in growth.

3. Positive Indicators:

• Compliance and Timely Filings: The company has filed accounts and confirmation statements on time with no overdue filings or regulatory issues.
• Positive Net Current Assets: With current assets of £78,420 against current liabilities of £54,820, the company maintains a positive working capital position (£23,600), suggesting short-term liquidity is adequate.
• Clear Ownership and Governance: Three directors with defined roles and shareholders controlling between 25-50% each indicate a balanced control structure without apparent governance red flags.

4. Due Diligence Notes:

• Review Business Model and Revenue Streams: Verify the nature of the company’s scientific and technical consulting activities (SIC 71122) and assess sustainability and revenue generation capacity.
• Examine Cash Flow Details: Since the accounts are unaudited and micro entity based, request internal cash flow statements or forecasts to confirm liquidity beyond the balance sheet snapshot.
• Investigate Related Party Transactions and Director Resignation: Explore reasons behind the resignation of one director within the first year and any related party dealings that could affect governance or financial stability.